INVARIANT LLC for CIGNA CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Educate policymakers on pharmacy issues related to TRICARE and H.R.2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to P.L 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; issues related to P.L 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; issues related to removing barriers to biosimilar medicine access; issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, INSULIN Act of 2023; S. 146, Cap Insulin Prices Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; issues related to mental health coverage, workforce, and mental health parity and the Behavioral Health Network and Directory Improvement Act and S. 2840, Bipartisan Primary Care and Health Workforce Act; and issues related commercial insurance, telehealth, and pharmacy benefits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW GRIFFIN New | Chief of Staff, Rep. Robert Latta (2019-2022); Comms Dir, Rep. Robert Latta (2016-2019); Press Sec, Rep. Erik Paulsen (2014-2016); Press Sec, Rep. Jaime Herrera Beutler (2013-2014); Staff Asst, Rep. Jaime Herrera Beutler (2011-2013) |
| JESSICA HATCHER | — |
| LINDLEY SHERER | — |
| ANNABELL MCWHERTER STOKES | — |
Medicare/Medicaid MMM
Educare policymakers on issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule; issues related to S.1967, the Patients Before Middlemen (PBM)Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; issues related to pharmaceutical affordability and access in Medicare under H.R.2880, the Protecting Patients Against PBM Abuses Act; H.R.5376, the Share the Savings with Seniors Act; H.R.5385, the Medicare PBM Accountability Act; and H.R. 4881, and issues related to point-of-sale rebates in Part D LIS under the Medicare program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW GRIFFIN New | Chief of Staff, Rep. Robert Latta (2019-2022); Comms Dir, Rep. Robert Latta (2016-2019); Press Sec, Rep. Erik Paulsen (2014-2016); Press Sec, Rep. Jaime Herrera Beutler (2013-2014); Staff Asst, Rep. Jaime Herrera Beutler (2011-2013) |
| JESSICA HATCHER | — |
| LINDLEY SHERER | — |
Pharmacy PHA
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127,the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the DRUG Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients(MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262,To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of th e 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; and issues related to Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for SeniorsAct; S.2254,the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822,the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disdosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health DATA Act;H.R. 4508, Hidden Fee Disdosure Act; H.R.3285 - Fairness for Patient Medications Act; S. Modernizing and Ensuring PBM Accountability Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW GRIFFIN New | Chief of Staff, Rep. Robert Latta (2019-2022); Comms Dir, Rep. Robert Latta (2016-2019); Press Sec, Rep. Erik Paulsen (2014-2016); Press Sec, Rep. Jaime Herrera Beutler (2013-2014); Staff Asst, Rep. Jaime Herrera Beutler (2011-2013) |
| JESSICA HATCHER | — |
| LINDLEY SHERER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.